Explore the words cloud of the ImmortaSTEM project. It provides you a very rough idea of what is the project "ImmortaSTEM" about.
The following table provides information about the project.
THE UNIVERSITY OF NOTTINGHAM
|Coordinator Country||United Kingdom [UK]|
|Total cost||149˙932 €|
|EC max contribution||149˙932 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2017-07-01 to 2018-12-31|
Take a look of project's partnership.
|1||THE UNIVERSITY OF NOTTINGHAM||UK (NOTTINGHAM)||coordinator||149˙932.00|
Under an ERC Advanced Grant, and subsequent PoC grant, Professor Shakesheff's team have invented a new intracellular delivery system that overcomes a problem in drug delivery in stem cell culture as well as regenerative medicine and other therapeutic approaches. The system, called GAG-binding enhanced transduction (GET), enables intracellular delivery of proteins, nucleic acids and particles into cells that resist other non-viral strategies. The work under ERC Advanced Grant and PoC funding has allowed exemplification of the delivery of proteins that promote pluripotency or differentiation, and delivery and expression of mRNA
This ImmortaSTEM: Proof-of-Concept Application will achieve 7 deliverables that together will generate a robust business plan for commercialisation of a specific application of GET to aid cell therapy attempts. This is a unique approach allowing expansion of a patient’s own cells as a therapy. We will begin by performing a comprehensive market analysis to test our view that GET could be used to expand valuable cells presently defined as challenging or impossible. Next we take account of the market analysis to refine our technical work resulting in a report that provides robust evidence of market required advantages of GET over competitor products for stem cell expansion. This technical work will include a consideration of manufacturing routes and costs of goods. In parallel with the technical work we will commission an independent freedom-to-operate report. Finally, we will initiate confidential discussions with potential partners and customers via face-to-face meetings in Europe and the US.
The final business plan will establish the technical and commercial feasibility of our approaches in one or more of our target markets. We envisage that at the end of the ERC PoC grant we will attract substantial funding to rapidly progress product launches and licenses with significant impact on the regenerative medicine and cell therapy sectors.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMORTASTEM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IMMORTASTEM" are provided by the European Opendata Portal: CORDIS opendata.